CNS Pharmaceuticals, Inc.
Zurich
United States
142 articles about CNS Pharmaceuticals, Inc.
-
Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
5/8/2023
CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it has appointed Bettina M. Cockroft, M.D., M.B.A., to its Board of Directors as an independent director.
-
CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC
5/3/2023
CNS Pharmaceuticals, Inc. announced that it is investigating potential naked short selling of its stock and has retained well-known analytics firm, Shareholder Intelligence Services, LLC, to review the trading patterns of the Company's common stock.
-
CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
4/27/2023
CNS Pharmaceuticals, Inc. today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wednesday, May 3, 2023 at 12:00 PM ET.
-
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
4/10/2023
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company") today announced that over 100 patients have been enrolled in the Company's potentially pivotal study with their lead product candidate, Berubicin.
-
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
4/6/2023
CNS Pharmaceuticals, Inc. today announced it has received approval from the Italian Medicines Agency ("AIFA") Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
-
CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
4/3/2023
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company") today reported its financial results for the full year ended December 31, 2022 and provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer.
-
CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event
3/29/2023
CNS Pharmaceuticals, Inc. today announced that it will present at the Virtual Investor GBM Spotlight Event on Tuesday, April 4, 2023 at 3:00 PM ET.
-
CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues
3/13/2023
CNS Pharmaceuticals, Inc. today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley due to liquidity concerns.
-
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
3/9/2023
CNS Pharmaceuticals, Inc. today announced that the first patient in Switzerland has been enrolled in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
-
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
2/7/2023
CNS Pharmaceuticals, Inc. today announced that the first patient in Spain has been enrolled in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
-
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland
1/12/2023
CNS Pharmaceuticals, Inc today announced an investigator-initiated Phase 1b/2 trial evaluating the Company's novel anthracycline, Berubicin, which will be conducted at the Pomeranian Medical University (PUM) in Szczecin, Poland.
-
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event
1/5/2023
CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 10:00 AM ET.
-
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors
1/3/2023
CNS Pharmaceuticals, Inc. announced it has appointed Faith L. Charles as Chair of its Board of Directors.
-
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
12/8/2022
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company") today announced preliminary results from its ongoing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM).
-
CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event
12/5/2022
CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will participate in the Virtual Investor "Ask the CEO" Event on Tuesday, December 6, 2022 at 11:00 AM ET.
-
CNS Pharmaceuticals Announces Reverse Stock Split
11/28/2022
CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced a 1-for-30 reverse split of its common stock, effective at 4:01 PM ET.
-
CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/14/2022
CNS Pharmaceuticals, Inc. reported its financial results for the quarter ended September 30, 2022 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.
-
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
11/2/2022
CNS Pharmaceuticals, Inc. today announced the first patient in Europe has been enrolled and dosed in France in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
-
CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run
10/10/2022
CNS Pharmaceuticals, Inc. today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will participate in The American Brain Tumor Association's Breakthrough for Brain Tumors® 5K Run taking place Saturday, November 5, 2022 in Los Angeles, CA.
-
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
10/7/2022
CNS Pharmaceuticals Inc. today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.